This inventor holds 6 USPTO granted patents and 3 published patent applications and 5 EPO patents. Top assignees: Agendia B.v., Agendia N.v.. Active years: 2014-2018.
Location History:
- Utrecht, NL (2014 - 2015)
- Bilthoven, NL (2015 - 2018)
- Amsterdam, NL (2018)
Company Filing History:
Years Active: 2014-2018
Title: Paul Roepman: Innovator in Molecular Classification of Cancers
Introduction
Paul Roepman is a prominent inventor based in Utrecht, Netherlands. He has made significant contributions to the field of molecular classification of cancers, particularly breast and colorectal cancers. With a total of 6 patents to his name, Roepman's work has the potential to greatly impact cancer diagnosis and treatment strategies.
Latest Patents
Roepman's latest patents include innovative methods for the molecular classification of breast cancer. This invention focuses on typing samples from breast cancer patients, specifically classifying the cancer based on the presence or absence of Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal growth factor Receptor 2 (HER2). The methods developed allow for the classification of breast cancer as ER positive, triple negative, and HER2+. Additionally, he has developed methods for the molecular classification of colorectal cancers. This invention relates to typing samples from colorectal cancer patients based on RNA expression levels in cancer cells. It also provides strategies for determining treatment options for patients suffering from colorectal cancer.
Career Highlights
Throughout his career, Paul Roepman has worked with notable companies such as Agendia B.V. and Agendia N.V. His expertise in molecular classification has positioned him as a key figure in cancer research and diagnostics.
Collaborations
Roepman has collaborated with esteemed colleagues, including Annuska Maria Glas and Oscar Krijgsman. These partnerships have further enhanced his research and contributions to the field.
Conclusion
Paul Roepman's innovative work in molecular classification of cancers showcases his dedication to improving cancer diagnosis and treatment. His patents reflect a commitment to advancing medical science and providing better outcomes for patients.